Overview

Botulinum Toxin Type A for Foot Dystonia-associated Pain in Parkinson's Disease

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
To study the effects of Botulinum toxin type A (BTXA) in the treatment of foot dystonia-associated pain in Parkinson's disease
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Calgary
Collaborator:
Allergan
Treatments:
abobotulinumtoxinA
Botulinum Toxins
Botulinum Toxins, Type A